Hyperthermia and liposomal encapsulated doxorubicin

Israel Medical Association Journal

Volumn 5, Issue 6, 2003, Pages 407-409

  Ben Yosef, Rami ^a,c   Gipps, Maya ^b   Zeira, Michael ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Caelyx; Doxil; Hyperthermia; Liposomal doxorubicin; Mice

Indexed keywords

CELLS; THERMAL EFFECTS; TUMORS;

TUMOR VOLUME;

DRUG THERAPY;

DOXORUBICIN; LIPOSOME; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENCAPSULATION; FEMALE; HYPERTHERMIC THERAPY; LUNG TUMOR; MONOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; TIME; TUMOR CELL; TUMOR VOLUME; WEIGHT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG ADMINISTRATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAVENOUS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038678957     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gabon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 1992;10:703-8.
2. Working PK, Dayan AD. Pharmacological-toxicological expert report - Caelyx™ (Stealth Liposomal Doxorubicin HCL). Hum Exp Toxicol 1996;15:751-85.
3. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol coated liposomes. Cancer Res 1994;54:987-92.
4. Gabizon A, Goren D, Horowitz AT. Long-circulating liposomes for drug delivery in cancer therapy: Reviews of bio-distribution studies in tumor-bearing animals. Ad Drug Deliver Rev 1997;24:337-44.
5. Vaage J, Donovan D, Uster P, Working P. Tumor uptake of doxorubicin in polyethylene-glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997;75:482-6.
6. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
7. Sewart S, Harrington KJ. The biodistribution and pharmacokinetics of Stealth liposomes in patients with solid tumors. Oncology 1997;11(Suppl 11):33-7.
8. Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by Stealth liposomes. Cancer 1999;86:72-8.
9. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhrist MW, Papahadjopoulos D. Thermosensitive liposomes: Extravasations and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996;36:1177-87.
10. Van Bree C, Krooshoop JJ, Rietbroek RC, Kipp JB, Bakker PJ: Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res 1996;56:563-8.
11. Kong G, Dewhisrt MW. Hyperthermia and liposomes. Int J Hyperthermia 1999;15:345-70.
12. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001; 61:3027-32.
13. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release. Cancer Res 2000;60:6950-7.
14. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature sensitive liposome for use with mild hyperthermia characterization and testing in a human tumor xenograft model. Cancer Res 2000;60:1197-201
15. Yuyama Y, Tsujimoto M, Fujimoto Y, Oku N. Potential usage of thermosensitive liposomes for site specific delivery of cytokines. Cancer Lett 2000;155:71-7.
16. Nishita T. Heat sensitive liposomes containing cisplatin and localised hyperthermia in treatment of murine tumor. Osaka City Med J 1998;44:73-83.
17. Sharma D, Chelvi TP, Kaur J, Ralhan R. Thermosensitive liposomal taxol formulation: Heat mediated targeted drug delivery in murine melanoma. Melanoma Res 1998;8:240-4.
18. Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731-44.
19. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996;12:3-20.
20. Van Der Zee J, Gonzalez Gonzalez D, Van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicenter trial. Dutch Deep Hyperthermia Group. Lancet 2000;355(9210):1119-25.
21. Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 1994;28:163-9.
22. Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/-hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:287-95.
23. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001;17:1-18.